Oric Pharmaceuticals Inc. (ORIC)
Stock Price:
$23.62 USD
-0.29 (-1.19%)
Updated Jul 16, 2020 1:47 PM EDT - Market open
Key Info
| Market Cap |
706.16M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
29.90M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 16, 2020 |
| Last Price |
$23.62 |
| Previous Close |
$23.90 |
| Change ($) |
-0.29 |
| Change (%) |
-1.19% |
| Day's Open |
23.69 |
| Day's Range |
23.06 - 23.95 |
| Day's Volume |
49,038 |
| 52-Week Range |
22.37 - 40.67 |
More Stats
| Market Cap |
706.16M |
| Enterprise Value |
626.72M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.90M |
| Float |
16.21M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.03M |
| Short Ratio |
9.24 |
| Short % of Float |
13.81% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
9.76 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
79.44M |
| Net Cash / Share |
2.66 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-25.36% |
| ROE |
-41.10% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$42.20*
(78.70% upside)
Low
35.0
Current: 23.62
High
48.0
Target: 42.20
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -28.57 | -22.37 |
| Net Income | -26.88 | -21.36 |
| Shares Outstanding | 1.90 | 1.73 |
| Earnings Per Share | -14.15 | -12.32 |
| Operating Cash Flow | -23.53 | -20.68 |
| Capital Expenditures | -0.77 | -0.53 |
| Free Cash Flow | -24.30 | -21.21 |
| Cash & Equivalents | 89.16 | 42.64 |
| Net Cash / Debt | 89.16 | 42.64 |
| Assets | 94.09 | 46.73 |
| Liabilities | 6.12 | 3.89 |
| Book Value | -90.08 | -64.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Oric Pharmaceuticals Inc. |
| Country |
United States |
| Employees |
57 |
| CEO |
Jacob M. Chacko |
Stock Information
| Ticker Symbol |
ORIC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ORIC |
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.